ACAD
32.08
-0.51
-1.56%
AEMD
0.24
+0.01
+5.73%
APRI
1.89
+0.02
+1.07%
ARNA
4.24
-0.13
-2.97%
ATEC
1.4
-0.05
-3.45%
CNAT
6.99
-0.13
-1.83%
CRXM
0.185
-0.01
-5.3361%
CYTX
1.14
-0.04
-3.39%
DXCM
61.64
-0.7
-1.12%
GNMK
12.23
-0.75
-5.78%
HALO
14.39
+0.11
+0.77%
ILMN
182.695
-2.945
-1.586%
INNV
0.15
+0.01
+7.2143%
INO
8.46
+0.3
+3.68%
ISCO
0.058
0.00
+0.346%
ISIS
61.616
-2.054
-3.2257%
LGND
77.35
+0.24
+0.31%
LPTN
2.45
-0.02
-0.81%
MBVX
1.8
-0.07
-3.7487%
MEIP
1.815
+0.025
+1.397%
MNOV
3.5
0.00
0.00%
MRTX
28.98
-0.34
-1.16%
MSTX
0.489
+0.004
+0.8660%
NBIX
39.03
-0.68
-1.71%
NUVA
45.26
-0.73
-1.59%
ONCS
0.325
-0.01
-2.985%
ONVO
3.75
+0.21
+5.93%
OREX
7.77
-0.06
-0.7676%
OTIC
35.57
+0.21
+0.59%
QDEL
26.495
-0.485
-1.798%
RCPT
164.974
+0.084
+0.0508%
RGLS
17.125
+0.185
+1.092%
RMD
70.734
-1.046
-1.4578%
SCIE
0.029
-0.001
-2.6667%
SPHS
0.595
+0.016
+2.7639%
SRNE
11.4
-0.16
-1.38%
TROV
6.745
-0.065
-0.954%
VICL
0.94
-0.005
-0.5609%
VOLC
17.99
0.00
0.00%
ZGNX
1.4
+0.03
+2.19%
ACAD
32.08
-0.51
-1.56%
AEMD
0.24
+0.01
+5.73%
APRI
1.89
+0.02
+1.07%
ARNA
4.24
-0.13
-2.97%
ATEC
1.4
-0.05
-3.45%
CNAT
6.99
-0.13
-1.83%
CRXM
0.185
-0.01
-5.3361%
CYTX
1.14
-0.04
-3.39%
DXCM
61.64
-0.7
-1.12%
GNMK
12.23
-0.75
-5.78%
HALO
14.39
+0.11
+0.77%
ILMN
182.695
-2.945
-1.586%
INNV
0.15
+0.01
+7.2143%
INO
8.46
+0.3
+3.68%
ISCO
0.058
0.00
+0.346%
ISIS
61.616
-2.054
-3.2257%
LGND
77.35
+0.24
+0.31%
LPTN
2.45
-0.02
-0.81%
MBVX
1.8
-0.07
-3.7487%
MEIP
1.815
+0.025
+1.397%
MNOV
3.5
0.00
0.00%
MRTX
28.98
-0.34
-1.16%
MSTX
0.489
+0.004
+0.8660%
NBIX
39.03
-0.68
-1.71%
NUVA
45.26
-0.73
-1.59%
ONCS
0.325
-0.01
-2.985%
ONVO
3.75
+0.21
+5.93%
OREX
7.77
-0.06
-0.7676%
OTIC
35.57
+0.21
+0.59%
QDEL
26.495
-0.485
-1.798%
RCPT
164.974
+0.084
+0.0508%
RGLS
17.125
+0.185
+1.092%
RMD
70.734
-1.046
-1.4578%
SCIE
0.029
-0.001
-2.6667%
SPHS
0.595
+0.016
+2.7639%
SRNE
11.4
-0.16
-1.38%
TROV
6.745
-0.065
-0.954%
VICL
0.94
-0.005
-0.5609%
VOLC
17.99
0.00
0.00%
ZGNX
1.4
+0.03
+2.19%
Home » Biography: Diana Wetmore, Ph.D.

Biography: Diana Wetmore, Ph.D.

Dr. Diana R. Wetmore is VP of Business Development and Alliances for Emerald BioStructures, and has an extensive background operating at the interface of business and science in the biotechnology and pharmaceutical industries. Her role at Emerald, a CRO providing structural biology services, includes building the client base through growth and diversification of services as well as business development support for ongoing projects. Prior to joining Emerald BioStructures, Dr. Wetmore was Vice President of Alliance Management for Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), where she managed the strategic planning process for the CF Foundation supported therapeutics pipeline, identified and launched multiple new discovery and development projects with industry collaborators. During this period her efforts helped shepherd many compounds and biologics into the clinical development pipeline. Prior to joining CFFT, Dr. Wetmore held positions in the pharmaceutical and biotechnology industries. At DuPont Merck Pharmaceuticals (now Bristol Myers Squibb), she was part of the crystallography group and studied protein-protein and protein-ligand interactions using calorimetric methods. During her 5-year tenure at Scriptgen Pharmaceuticals, now Anadys, she led the fragment discovery and drug design group before moving to Sr. Director of R&D Project Management. At Geneprot, Inc., she served as the Chief Technical Officer for that proteomics-based target discovery company. Dr. Wetmore obtained her PhD in biochemistry at the University of Calgary in Canada, where her interest was in studying the contributions of ligand binding to protein folding and stability. Her publications cover a range of scientific pursuits, including: protein biophysics, molecular modeling of target-ligand interactions, biomarker discovery and bioinformatics.